Application of PCSK9 inhibitors in practice: Challenges and opportunities

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

Although the discovery of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and development of therapeutic antagonists represent a major triumph of modern clinical medicine, efforts to implement PCSK9 inhibitors (PCSK9i) in patient care have been sobering. This practical guide examines the barriers and opportunities for the successful application of pharmacological inhibition of PCSK9 in clinical practice through introduction of a new model of care delivery-the PCSK9i clinic.

Original languageEnglish (US)
Pages (from-to)499-501
Number of pages3
JournalCirculation Research
Volume121
Issue number5
DOIs
StatePublished - Aug 1 2017

    Fingerprint

Keywords

  • Angina
  • Cholesterol
  • Health
  • Insurance
  • LDL
  • Patient care
  • Secondary prevention
  • Unstable

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this